JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma.

ABSTRACT: Steroids are the standard treatment for allergic airway inflammation in asthma, but steroid-refractory asthma poses a challenge. Group 2 innate lymphoid cells (ILC2s), such as T helper 2 (T_H2) cells, produce key asthma-related type 2 cytokines. Recent insights from mouse and human studies indicate a potential connection between ILC2s and steroid-resistant asthma. Here, we highlight that lung ILC2s, rather than T_H2 cells, can develop steroid resistance, allowing them to persist and maintain their disease-driving activity even during steroid treatment. The emergence of multipotent IL-5⁺IL-13⁺IL-17A⁺ ILC2s is associated with steroid-resistant ILC2s. The Janus kinase 3 (JAK3)/signal transducer and activator of transcription (STAT) 3, 5, an

SUBMITTER: Kim J 

PROVIDER: S-EPMC10732531 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature